Treating Adhd – the Basics Ohsujanuary 6, 2019

Total Page:16

File Type:pdf, Size:1020Kb

Treating Adhd – the Basics Ohsujanuary 6, 2019 TREATING ADHD – THE BASICS OHSUJANUARY 6, 2019 - JAY S. KOTHARI, MD - KEITH CHENG, MD $$$ DISCLOSURES $$$ OHSUNO FINANCIAL OR COMMERCIAL INTERESTS LEARNING OBJECTIVES • DIAGNOSIS AND DIFFERENTIAL DIAGNOSES OF ADHD • GENERAL PRINCIPLES OF ADHD PSYCHOPHARMACOLOGY • BE ABLE TO PRESCRIBE STIMULANTS • LEARN ABOUT NON-STIMULANT AND BEHAVIORAL OHSUAPPROACHES TO TREATMENT •Diagnosis, diagnosis, diagnosis – thorough psychiatric evaluation •Use of rating scales, Labs, EKG •Difference in pharmacokinetics “CHILDREN • Liver Tissue • GFR ARE NOT • TBW • Fat tissue content LITTLE • GI maturity ADULTS” •Difference in pharmacodynamics – different efficacy and tolerability / side effect profile •Safety/efficacy – being aware of black box warnings in OHSUchildren DSM-5 CRITERIA .Symptoms must be present for at least 6 months and impair social/academic/occupational function and be inconsistent with chronologic age .Some symptoms were present before 12 yrs .Present in 2 or more settings​ .Symptoms not due to other mental disorders​ OHSU.Inattention - must have 6 of 9 criteria​ .Hyperactivity - must have 6 of 9 criteria INATTENTIVE ADHD Often does not give close attention to details or makes careless mistakes in schoolwork, work, or other activities (e.g., overlooks or misses details, work is inaccurate).​ Often has difficulty sustaining attention in tasks or play activities (e.g., has difficulty remaining focused during lectures, conversations, or reading lengthy writings)​ Often does not seem to listen when spoken to directly (e.g., mind seems elsewhere, even in the absence of any obvious distraction). Often does not follow through on instructions and fails to finish schoolwork, chores, or duties in the workplace (e.g., starts tasks but quickly loses focus and is easily sidetracked; fails to finish schoolwork, household chores, or tasks in the workplace). Often has difficulty organizing tasks and activities (e.g., difficulty managing sequential tasks; difficulty keeping materials and belongings in order; messy, disorganized, work; poor time management; tends to fail to meet deadlines) Often avoids, dislikes, or is reluctant to engage in tasks that require sustained mental effort (e.g., schoolwork or homework; for older adolescents and adults, preparing reports, completing forms, or reviewing lengthy papers). Often loses things needed for tasks and activities (e.g., school materials, pencils, books, tools, wallets, keys, paperwork, eyeglasses, or mobile telephones) OHSUIs often easily distracted by extraneous stimuli (for older adolescents and adults, may include unrelated thoughts). Is often forgetful in daily activities (e.g., chores, running errands; for older adolescents and adults, returning calls, paying bills, keeping appointments) HYPERACTIVE/IMPULSIVE ADHD .Often fidgets with hands or feet or squirms in seat. .Often leaves seat in situations when remaining seated is expected (e.g., leaves his or her place in the classroom, office or other workplace, or in other situations that require remaining seated) .Often runs about or climbs in situations where it is inappropriate. (In adolescents or adults, may be limited to feeling restless). .Often unable to play or engage in leisure activities quietly. .Is often "on the go" or often acts as if "driven by a motor" (e.g., is unable or uncomfortable being still for an extended time, as in restaurants, meetings, etc; may be experienced by others as being restless and difficult to keep up with). .Often talks excessively.​ .Often blurts out answers before questions have been completed (e.g., completes people’s sentences and “jumps the gun” in conversations, cannot wait for next turn in conversation)​ OHSU.Often has trouble waiting his or her turn (e.g., while waiting in line). Often interrupts or intrudes on others (e.g., butts into conversations, games, or activities; may start using other people’s things without asking or receiving permission; for adolescents and adults, may intrude into or take over what others are doing). WHAT WORKS BEST? •Well-established EBP’s: Behavioral Management Training (BMT) & Behavioral Contingency Management in the classroom •MTA study •MTA follow-up study OHSU•Interventions for Preschool kids at high-risk for ADHD: Meta-analysis CHILDHOOD​ ADULTHOOD​ Inattention​ Difficulty sustaining attention​ Difficulty sustaining attention​ Appears not to listen​ Makes careless errors​ Cannot organize, focus​ Easily distracted/forgetful​ Loses important items​ Hard to finish tasks​ Poor concentration​ Disorganized, misplaces things​ Hyperactivity​ Squirmy, Fidgety​ Inefficiencies in work​ Cannot stay seated​ Can’t sit through meetings​ Cannot wait for turn​ Internal restlessness​ “Drive by a motor”​ Over multitasks​ Talks excessively​ Impulsivity​ Blurts out answers​ Impulsive Job changes​ Cannot wait in line​ Drives too fast​ Constantly intrudes and interrupts others​ Interrupts others​ OHSUEasily frustrated​ CHILDHOOD VS ADULTHOOD IMPACT OHSUON LIFE DIFFERENTIAL DIAGNOSIS . Psychiatric conditions: . Children: low self-esteem, anxiety, depression, conduct disorder, oppositional defiant disorder, obsessive-compulsive disorder, poor social skills . Adolescents/adults: alcohol/drug abuse, anxiety, depression, personality disorder, bipolar disorder . General medical conditions - Hypothyroidism, severe anemia, lead poisoning, chronic illness, hearing or vision impairment, seizures, TBIs, FAS, Vit D deficiency, med s/e . Neurological conditions - Sleep disorders, Tourette’s syndrome, epilepsy (petit mal), OHSUspecific and general learning difficulties . Environmental factors - Unsafe or disruptive learning environment, school curriculum not matched to child’s ability, family dysfunction or poor parenting, child abuse/neglect, parental psychopathology, poor sleep (internet surfing for e.g.), bullying NEUROANATOMY OF ADHD OHSU http://www.bioscience.org/2000/v5/d/himelste/fulltext.htm •Stimulants (2 classes): • Immediate-release: Ritalin, Adderall, Focalin • Long-acting: Concerta, Adderall XR, Vyvanse, Focalin XR • Pro-drugs: Vyvanse •NRIs: Atomoxetine •Noradrenergic Modulators (alpha-2 agonists): • Short-acting: Tenex, Catapres • Long-acting: Intuniv, Kapvay •“Experimental” or off-label: • NDRI: Wellbutrin • SNRIs: Venlafaxine, Duloxetine • Modafinil (DRI) • Antipsychotics: Risperidone, 1st generation antipsychotics OHSU• Amantadine • TCAs STIMULANTS .“Stimulate” the brain to focus .70-85% response rate, effect size ~0.95 .Mechanisms of action .D vs L isomers .Effects/ side effects .Weight-based dosing or not? .Duration of action (AM, HW, wkn) OHSU.Drug holidays? Do: ◦ Increase dosing slowly to maximum of therapeutic range if no side effects ◦ Assess duration of action (what to do if medication is wearing off too early? I.e. increase or bunch up?) DOS AND ◦ Use input from school DONTS OF ◦ Try a different stimulant if 1st or 2nd trial fails DOSING Don’t: ◦ Begin too high (start low, go slow, especially if OHSUdev. delay) OHSU MPH FORMULATIONS By formulation: Liquid form Solutabs Cleaved: D-form (Focalin) Patch: 9 hours on, 15 hours off Delayed phase (Delexis system – just approved, will hit market 2019) By duration: Short acting: 3-4 hours Intermediate-acting: ER, LA**, CD Long-acting: Concerta (OROS) OHSU. FDA-approved max daily dose for MPH is 60mg, Concerta 72mg . ** Can sprinkle on food OHSU COMPARISON OF DOSE-CURVES DOSING MPH .According to AACAP, start at lowest dose (10mg BID), titrate up once a week (outpatient) .Other method: Weight based - Start ~0.5mg/kg/day up to 2mg/kg/day, titrate up every couple of days if needed (inpatient) .Focalin has to be dosed based on AMP dosing since it is a D-isomer (twice as potent) .Concerta dosing is higher than Ritalin (for e.g. 5mg BID/TID = 18mg Concerta, 15mg BID/TID = 54mg) – look for clinical relevance .Daytrana Patch – ~1.5x more potent than oral dose, 9 hours on, 15 hours off (on hip) OHSU.Reassess every year for continued need/dose AMP FORMULATIONS By formulation: By duration: • Amphetamine – ER, ODT, liquid • Short-acting: 3-4 hours • Methamphetamine (not used, • Intermediate-acting: 6-8 hours “Desoxyn” – FDA approved for • Long-acting: Vyvanse obesity) • Dextro-amphetamine - IR, ER, liquid OHSU• Mixed salts (D, L) – IR, ER • Pro-drug (Vyvanse) DOSING AMP .According to AACAP, start at lowest dose (5mg BID), titrate up once a week (outpatient) .Other method: Weight based - Start ~0.25mg/kg/day up to 1mg/kg/day, titrate up every couple of days (inpatient) .Remember, mixed salts are usually 3:1 D vs L isomers, although Evekeo which is 1:1 – manufacturers say this leads to less s/e .Vyvanse is a pro-drug that converts to all D-AMP: needs 2 hours to activate. Less toxicity, abuse, diversion OHSU.Reassess every year for continued need/dose WHAT TO DO IF… .15 y/o weighing 50kg comes in with dx of ADHD? Med/dosing . Has comorbid ODD and impulsivity . Has comorbid tic disorder . Tics get worse after use of stimulant . Has comorbid SUD . Has appetite loss after starting stimulant . Has disruptive sleep to start out with . Has a family hx of CV disease OHSU. Has poor insurance Do stimulants cause addiction? According to a study in the Br J Psychiatry July 11, 2013, stimulant medications appear to lower the risk for substance abuse disorders in adolescents with ADHD In a large, prospective, longitudinal study investigators from the SUNY found that adolescents with ADHD who were not treated with a stimulant medication for their disorder had a 2-fold increased risk of developing an SUD compared with their counterparts who were treated. Untreated
Recommended publications
  • Addictions and the Brain
    9/18/2012 Addictions and the Brain TAAP Conference September 14, 2012 Acknowledgements • La Hacienda Treatment Center • American Society of Addiction Medicine • National Institute of Drug Abuse © 2012 La Hacienda Treatment Center. All rights reserved. 1 9/18/2012 Definition • A primary, progressive biochemical, psychosocial, genetically transmitted chronic disease of relapse who’s hallmarks are denial, loss of control and unmanageability. DSM IV Criteria for dependency: At least 3 of the 7 below 1. Withdrawal 2. Tolerance 3. The substance is taken in larger amounts or over a longer period than was intended. 4. There is a persistent desire or unsuccessful efforts to cut down or control substance use. 5. A great deal of time is spent in activities necessary to obtain the substance, use the substance, or recover from its effects. 6. Important social, occupational, or recreational activities are given up or reduced because of the substance use. 7. The substance use is continued despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by the substance. © 2012 La Hacienda Treatment Center. All rights reserved. 2 9/18/2012 Dispute between behavior and disease Present understanding of the Hypothalamus location of the disease hypothesis. © 2012 La Hacienda Treatment Center. All rights reserved. 3 9/18/2012 © 2012 La Hacienda Treatment Center. All rights reserved. 4 9/18/2012 © 2012 La Hacienda Treatment Center. All rights reserved. 5 9/18/2012 Dispute regarding behavior versus disease © 2012 La Hacienda Treatment Center. All rights reserved. 6 9/18/2012 © 2012 La Hacienda Treatment Center.
    [Show full text]
  • ADHD Parents Medication Guide Revised July 2013
    ADHD Parents Medication Guide Revised July 2013 Attention-Deficit/Hyperactivity Disorder Prepared by: American Academy of Child & Adolescent Psychiatry and American Psychiatric Association Supported by the Elaine Schlosser Lewis Fund Physician: ___________________________________________________ Address: ___________________________________________________ ___________________________________________________ ___________________________________________________ Phone: ___________________________________________________ Email: ___________________________________________________ ADHD Parents Medication Guide – July 2013 2 Introduction Attention-Deficit/Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder characterized by difficulty paying attention, excessive activity, and impulsivity (acting before you think). ADHD is usually identified when children are in grade school but can be diagnosed at any time from preschool to adulthood. Recent studies indicate that almost 10 percent of children between the ages of 4 to 17 are reported by their parents as being diagnosed with ADHD. So in a classroom of 30 children, two to three children may have ADHD.1,2,3,4,5 Short attention spans and high levels of activity are a normal part of childhood. For children with ADHD, these behaviors are excessive, inappropriate for their age, and interfere with daily functioning at home, school, and with peers. Some children with ADHD only have problems with attention; other children only have issues with hyperactivity and impulsivity; most children with ADHD have problems with all three. As they grow into adolescence and young adulthood, children with ADHD may become less hyperactive yet continue to have significant problems with distraction, disorganization, and poor impulse control. ADHD can interfere with a child’s ability to perform in school, do homework, follow rules, and develop and maintain peer relationships. When children become adolescents, ADHD can increase their risk of dropping out of school or having disciplinary problems.
    [Show full text]
  • Anti-Inflammatory Effects of Amantadine and Memantine
    Journal of Personalized Medicine Communication Anti-Inflammatory Effects of Amantadine and Memantine: Possible Therapeutics for the Treatment of Covid-19? Félix Javier Jiménez-Jiménez 1,* , Hortensia Alonso-Navarro 1 , Elena García-Martín 2 and José A. G. Agúndez 2 1 Section of Neurology, Hospital Universitario del Sureste, Arganda del Rey, E-28500 Madrid, Spain; [email protected] 2 University Institute of Molecular Pathology Biomarkers, UNEx. ARADyAL Instituto de Salud Carlos III, E-10071 Cáceres, Spain; [email protected] (E.G.-M.); [email protected] (J.A.G.A.) * Correspondence: [email protected]; Tel.: +34-636968395 Received: 2 October 2020; Accepted: 6 November 2020; Published: 9 November 2020 Abstract: We have reviewed current data on the anti-inflammatory effects of amantadine and memantine in clinical and in vivo models of inflammation, and we propose that these effects have potential interest for the treatment of the SARS-CoV-2 infection (COVID-19 disease). To that end, we performed a literature search using the PubMed Database from 1966 up to October 31 2020, crossing the terms “amantadine” and “memantine” with “inflammation” and “anti-inflammatory”. Amantadine and/or memantine have shown anti-inflammatory effects in chronic hepatitis C, in neuroinflammation induced by sepsis and by lipopolysaccharides, experimental models of multiple sclerosis, spinal cord injury, and respiratory diseases. Since the inflammatory response is one of the main pathogenetic mechanisms in the progression of the SARS-CoV-2 infection, anti-inflammatory effects of amantadine and memantine could be hypothetically useful in the treatment of this condition. This potential utility deserves further research. Keywords: amantadine; memantine; anti-inflammatory effects; SARS-Cov-2; COVID-19; therapy 1.
    [Show full text]
  • Sensory Processing in Children with ADHD: a Classroom Study and Rational Item Analysis Jason Mathison Philadelphia College of Osteopathic Medicine, [email protected]
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Philadelphia College of Osteopathic Medicine: DigitalCommons@PCOM Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Psychology Dissertations Student Dissertations, Theses and Papers 2012 Sensory Processing in Children with ADHD: A Classroom Study and Rational Item Analysis Jason Mathison Philadelphia College of Osteopathic Medicine, [email protected] Follow this and additional works at: http://digitalcommons.pcom.edu/psychology_dissertations Part of the Psychology Commons Recommended Citation Mathison, Jason, "Sensory Processing in Children with ADHD: A Classroom Study and Rational Item Analysis" (2012). PCOM Psychology Dissertations. Paper 212. This Dissertation is brought to you for free and open access by the Student Dissertations, Theses and Papers at DigitalCommons@PCOM. It has been accepted for inclusion in PCOM Psychology Dissertations by an authorized administrator of DigitalCommons@PCOM. For more information, please contact [email protected]. Philadelphia College of Osteopathic Medicine Department of Psychology SENSORY PROCESSING IN CHILDREN WITH ADHD: A CLASSROOM STUDY AND RATIONAL ITEM ANALYSIS Jason Mathison Submitted in Partial Fulfillment of the Requirements for the Degree of Doctor of Psychology May 2012 Committee Members' Signatures: George McCloskey, PhD, Chairperson Lisa Hain, PsyD Dr William Young Robert A DiTomasso, PhD, ABPP, Chair, Department of Psychology iii Acknowledgements This dissertation is dedicated to my wife, family, and supportive committee. First and foremost, to my wife Nicole Mathison, who has provided me with endless support, love, and patience with my difficult schedule and long commute over the last three years. During this process, she has lost her father, two grandmothers, and her beloved cat Ruby.
    [Show full text]
  • Positron Emission Tomography Studies of Potential Mechanisms Underlying Phencyclidine-Induced Alterations in Striatal Dopamine
    Neuropsychopharmacology (2003) 28, 2192–2198 & 2003 Nature Publishing Group All rights reserved 0893-133X/03 $25.00 www.neuropsychopharmacology.org Positron Emission Tomography Studies of Potential Mechanisms Underlying Phencyclidine-Induced Alterations in Striatal Dopamine ,1,2 2 1,2 Wynne K Schiffer* , Jean Logan and Stephen L Dewey 1SUNY Stony Brook, Department of Neurobiology and Behavior, Stony Brook, NY, USA; 2Brookhaven National Laboratory, Chemistry Department, Upton, NY, USA 11 Positron emission tomography (PET), in combination with C-raclopride, was used to examine the effects of phencyclidine (PCP) on dopamine (DA) in the primate striatum. In addition, we explored the hypotheses that GABAergic pathways as well as molecular targets beyond the N-methyl-D-aspartate (NMDA) receptor complex (ie dopamine transporter proteins, DAT) contribute to PCP’s effects. In 11 the first series of experiments, C-raclopride was administered at baseline and 30 min following intravenous PCP administration. In the second series of studies, g-vinyl GABA (GVG) was used to assess whether enhanced GABAergic tone altered NMDA antagonist- induced changes in DA. Animals received an initial PET scan followed by pretreatment with GVG (300 mg/kg), then PCP 30 min prior to 11 a second scan. Finally, we explored the possible contributions of DAT blockade to PCP-induced increases in DA. By examining C- cocaine binding a paradigm in which PCP was coadministered with the radiotracer, we assessed the direct competition between these 11 two compounds for the DAT. At 0.1, 0.5, and 1.0 mg/kg, PCP decreased C-raclopride binding by 2.1, 14.9 7 2.2 and 8.18 7 1.1%, 11 respectively.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,469,601 B2 Vacher Et Al
    USOO94.69601 B2 (12) United States Patent (10) Patent No.: US 9,469,601 B2 Vacher et al. (45) Date of Patent: Oct. 18, 2016 (54) AMINOCYCLOBUTANE DERIVATIVES, FOREIGN PATENT DOCUMENTS METHOD FOR PREPARING SAME AND THE EP 0 747 348 A1 12/1996 USE THEREOF AS DRUGS EP O747348 A1 * 12, 1996 ............. CO7B 57/OO WO WO 98.07447 A1 2, 1998 (71) Applicant: PIERRE FABRE MEDICAMENT, WO WO 99.12537 A1 3, 1999 Boulogne-Billancourt (FR) WO WO 99.52848 A1 10, 1999 WO WOOOO3716 A1 1, 2000 WO WOOO, 51607 A1 9, 2000 (72) Inventors: Bernard Vacher, Castres (FR); Elodie WO WO 03/06165.6 A1 T 2003 Blanc, Semalens (FR); Ronan WO WO O3,063797 A2 8, 2003 Depoortere, Castres (FR) WO WO 2006/081179 A1 8, 2006 WO WO 2008/092.955 A1 8, 2008 WO WO 2009/O29618 A1 3, 2009 (73) Assignee: PIERRE FABRE MEDICAMENT, WO WO 2009/06961.0 A1 6, 2009 Boulogne-Billancourt (FR) WO WO 2009/092324 A1 T 2009 WO WO 2010/036937 A1 4/2010 (*) Notice: Subject to any disclaimer, the term of this WO WO 2010/037533 A1 4, 2010 patent is extended or adjusted under 35 (Continued) U.S.C. 154(b) by 0 days. OTHER PUBLICATIONS (21) Appl. No.: 14/649,448 Aarts et al., “Novel Treatment of Excitotoxicity: Targeted Disrup (22) PCT Filed: Dec. 4, 2013 tion of Intracellular Signalling from Glutamate Receptors,” Bio chemical Pharmacology, vol. 66, 2003, pp. 877-886. (86). PCT No.: PCT/EP2013/075481 (Continued) S 371 (c)(1), (2) Date: Jun.
    [Show full text]
  • ADHD Medication and Treatment Free Downloads the Latest Information on Managing Medication, Starting Behavior Therapy, Evaluating Alternative Treatments, and More
    The Ultimate Guide to ADHD MEveryethingd you neied cto knaow abtout miedoicationn options, achieving optimal benefits, and overcoming side effects. Includes MEDICATION TRACKING LOGS BY THE EDITORS OF WITH LAURIE DUPAR, PMHNP, AND WILLIAM DODSON, M.D. Expert eBook A trusted source of advice and information for families touched by attention-deficit disorder— and a voice of inspiration to help people with ADHD find success at home, at school, and on the job. additudemag.com/shop TERMS OF USE FOUNdER: Ellen Kingsley (1951-2007) Copyright © 2018 by New Hope Media. All rights reserved. Editor IN ChIEF: Susan Caughman No part of this report may be reproduced or transmitted Editor: Wayne Kalyn in any form or by any means, electronic or mechanical, including photocopying, recording, faxing, e-mailing, staff posting online, or by any information storage and retrieval consulting creativE Director: Joseph Caserto system, without written permission from the Publisher. consulting art Director: Ron Anteroinen Managing Editor: Eve Gilman All trademarks and brands referred to herein are the Reporter: Devon Frye SENIOR Digital Editor: Janice Rodden property of their respective owners. All references to SOCIAL MEdIA Editors: Rebecca Brown Wright, Penny Williams ADDitude magazine and ADDitudeMag.com are trade- Digital MARKETING Director: Anni Rodgers marks of New Hope Media. Advertising: Anne Mazza Circulation: Sue Sidler CONTACT INFORMATION COPy Editor: Gene Jones WEB Editor: Hope Goodrich New Hope Media 646-366-0830 contributing Editors: 108 West 39th St, Suite 805 Carol Brady, Ph.D., and John Taylor, Ph.D. (Children) New York, NY 10018 Edward M. Hallowell, M.D. (Life) Sandy Maynard, M.S.
    [Show full text]
  • Phencyclidine: an Update
    Phencyclidine: An Update U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol, Drug Abuse and Mental Health Administration Phencyclidine: An Update Editor: Doris H. Clouet, Ph.D. Division of Preclinical Research National Institute on Drug Abuse and New York State Division of Substance Abuse Services NIDA Research Monograph 64 1986 DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administratlon National Institute on Drug Abuse 5600 Fishers Lane Rockville, Maryland 20657 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, DC 20402 NIDA Research Monographs are prepared by the research divisions of the National lnstitute on Drug Abuse and published by its Office of Science The primary objective of the series is to provide critical reviews of research problem areas and techniques, the content of state-of-the-art conferences, and integrative research reviews. its dual publication emphasis is rapid and targeted dissemination to the scientific and professional community. Editorial Advisors MARTIN W. ADLER, Ph.D. SIDNEY COHEN, M.D. Temple University School of Medicine Los Angeles, California Philadelphia, Pennsylvania SYDNEY ARCHER, Ph.D. MARY L. JACOBSON Rensselaer Polytechnic lnstitute National Federation of Parents for Troy, New York Drug Free Youth RICHARD E. BELLEVILLE, Ph.D. Omaha, Nebraska NB Associates, Health Sciences Rockville, Maryland REESE T. JONES, M.D. KARST J. BESTEMAN Langley Porter Neuropsychiatric lnstitute Alcohol and Drug Problems Association San Francisco, California of North America Washington, D.C. DENISE KANDEL, Ph.D GILBERT J. BOTV N, Ph.D. College of Physicians and Surgeons of Cornell University Medical College Columbia University New York, New York New York, New York JOSEPH V.
    [Show full text]
  • Dexmethylphenidate
    MICROMEDEX® Healthcare Series : Document Page 1 of 31 Case 3:09-cv-00080-TMB Document 78-23 Filed 03/24/2010 Page 1 of 105 DRUGDEX® Evaluations DEXMETHYLPHENIDATE 0.0 Overview 1) Class a) This drug is a member of the following class(es): Amphetamine Related CNS Stimulant 2) Dosing Information a) Dexmethylphenidate Hydrochloride 1) Adult a) Attention deficit hyperactivity disorder 1) extended-release: methylphenidate-naive patients, initial 10 mg ORALLY daily in the morning; adjust dose weekly in 10 mg increments; MAX 20 mg/day 2) extended-release: patients currently using methylphenidate, one-half the total daily dose of racemic methylphenidate; patients currently using dexmethylphenidate immediate-release may be switched to the same daily dose of dexmethylphenidate extended-release; MAX 20 mg/day 2) Pediatric a) safety and efficacy not established in patients under 6 years of age 1) Attention deficit hyperactivity disorder a) immediate-release (ages 6 years and older): methylphenidate-naive patients, initial 2.5 mg ORALLY twice daily; adjust dose weekly in 2.5 to 5 mg increments; MAX 20 mg/day (10 mg twice a day) b) immediate-release (ages 6 years and older): patients currently using methylphenidate, one-half the dose of racemic methylphenidate; MAX 20 mg/day (10 mg twice a day) c) extended-release (ages 6 years and older): methylphenidate-naive patients, initial 5 mg ORALLY in the morning; adjust dose weekly in 5 mg increments; MAX 20 mg/day(Prod Info FOCALIN XR(R) extended-release oral capsules, 2008) d) extended-release (ages 6 years
    [Show full text]
  • Treatment of Patients with Substance Use Disorders Second Edition
    PRACTICE GUIDELINE FOR THE Treatment of Patients With Substance Use Disorders Second Edition WORK GROUP ON SUBSTANCE USE DISORDERS Herbert D. Kleber, M.D., Chair Roger D. Weiss, M.D., Vice-Chair Raymond F. Anton Jr., M.D. To n y P. G e o r ge , M .D . Shelly F. Greenfield, M.D., M.P.H. Thomas R. Kosten, M.D. Charles P. O’Brien, M.D., Ph.D. Bruce J. Rounsaville, M.D. Eric C. Strain, M.D. Douglas M. Ziedonis, M.D. Grace Hennessy, M.D. (Consultant) Hilary Smith Connery, M.D., Ph.D. (Consultant) This practice guideline was approved in December 2005 and published in August 2006. A guideline watch, summarizing significant developments in the scientific literature since publication of this guideline, may be available in the Psychiatric Practice section of the APA web site at www.psych.org. 1 Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx. AMERICAN PSYCHIATRIC ASSOCIATION STEERING COMMITTEE ON PRACTICE GUIDELINES John S. McIntyre, M.D., Chair Sara C. Charles, M.D., Vice-Chair Daniel J. Anzia, M.D. Ian A. Cook, M.D. Molly T. Finnerty, M.D. Bradley R. Johnson, M.D. James E. Nininger, M.D. Paul Summergrad, M.D. Sherwyn M.
    [Show full text]
  • The Role of Inhibitory Control and Executive Functioning in Hyperactivity/ADHD
    ! "# $ % &'% () *' ("*+ '' +,"' -'*"+ --'*' . Dissertation for the Degree of Doctor of Philosophy in Psychology presented at Uppsala University in 2003 ABSTRACT Berlin, L. 2003. The Role of Inhibitory Control and Executive Functioning in Hyperactivity/ADHD. Acta Universitatis Upsaliensis. Comprehensive Summaries of Uppsala Dissertations from the Faculty of Social Sciences 120. 76 pp. Uppsala. ISBN 91-544-5513-1. This thesis examined inhibition, executive functioning and their possible relation to childhood problems of hyperactivity and inattention, in its clinical form referred to as Attention Deficit Hyper- activity Disorder (ADHD). Concurrent as well as longitudinal relations were of interest, and both clinical and non-clinical samples were studied. Study I demonstrated concurrent relations between executive inhibition and both hyperactivity and conduct problems in preschool. However, the relation between inhibition and conduct problems could be attributed to the large overlap between hyperactivity and conduct problems. In Study II, linear relations were found between executive inhibition and hyperactivity, whereas inhibition to the unfamiliar was related to hyperactivity, social initiative, as well as social anxiety. Non-linear analyses showed that children with high levels of both types of inhibition were at risk for developing low social initiative and social anxiety, whereas children with low levels of inhibition were at risk for developing hyperactivity, but at the same time protected from social anxiety. In Study III, executive inhibition was longitudinally related to ADHD symptoms in both school and at home for boys, but only in the school context for girls. Executive inhibition was also related to more general executive functioning deficits, and concurrent relations were found between executive functioning and ADHD symptoms, although in both cases only for boys.
    [Show full text]
  • Male Anorgasmia: from “No” to “Go!”
    Male Anorgasmia: From “No” to “Go!” Alexander W. Pastuszak, MD, PhD Assistant Professor Center for Reproductive Medicine Division of Male Reproductive Medicine and Surgery Scott Department of Urology Baylor College of Medicine Disclosures • Endo – speaker, consultant, advisor • Boston Scientific / AMS – consultant • Woven Health – founder, CMO Objectives • Understand what delayed ejaculation (DE) and anorgasmia are • Review the anatomy and physiology relevant to these conditions • Review what is known about the causes of DE and anorgasmia • Discuss management of DE and anorgasmia Definitions Delayed Ejaculation (DE) / Anorgasmia • The persistent or recurrent delay, difficulty, or absence of orgasm after sufficient sexual stimulation that causes personal distress Intravaginal Ejaculatory Latency Time (IELT) • Normal (median) à 5.4 minutes (0.55-44.1 minutes) • DE à mean IELT + 2 SD = 25 minutes • Incidence à 2-11% • Depends in part on definition used J Sex Med. 2005; 2: 492. Int J Impot Res. 2012; 24: 131. Ejaculation • Separate event from erection! • Thus, can occur in the ABSENCE of erection! Periurethral muscle Sensory input - glans (S2-4) contraction Emission Vas deferens contraction Sympathetic input (T12-L1) SV, prostate contraction Bladder neck contraction Expulsion Bulbocavernosus / Somatic input (S1-3) spongiosus contraction Projectile ejaculation J Sex Med. 2011; 8 (Suppl 4): 310. Neurochemistry Sexual Response Areas of the Brain • Pons • Nucleus paragigantocellularis Neurochemicals • Norepinephrine, serotonin: • Inhibit libido,
    [Show full text]